Galapagos NV
GLPG33.375USD
+0.665+2.03%
Market hours （ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
More Details of Galapagos NV Company
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
Ticker SymbolGLPG
Company nameGalapagos NV
IPO dateMay 06, 2005
CEOHenry Gosebruch
Number of employees704
Security typeOrdinary Share
Fiscal year-endMay 06
AddressGeneraal De Wittelaan L11 A3
CityMALINES (MECHELEN)
Stock exchangeEuronext Amsterdam
CountryBelgium
Postal code2800
Phone3215342900
Websitehttps://www.glpg.com/
Ticker SymbolGLPG
IPO dateMay 06, 2005
CEOHenry Gosebruch
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Elisabeth Svanberg
Ms. Elisabeth Svanberg
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Valeria Cnossen
Ms. Valeria Cnossen
Executive Vice President, General Counsel, Member of the Management Board
Executive Vice President, General Counsel, Member of the Management Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Revenue Breakdown
Currency: EURUpdated: Sun, Jul 6
Currency: EURUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionEUR
Name
Revenue
Proportion
United States
240.79M
87.35%
Europe
34.86M
12.65%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
Shareholder Types
Shareholders
Proportion
Hedge Fund
15.79%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
2.06%
Research Firm
0.38%
Sovereign Wealth Fund
0.18%
Bank and Trust
0.03%
Other
77.73%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
173
14.68M
22.27%
-2.24M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
2023Q3
221
19.52M
29.63%
-4.10M
2023Q2
254
20.05M
30.43%
-5.06M
2023Q1
285
18.55M
28.15%
-1.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
3.96M
6.01%
+1.42M
+55.71%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.48M
2.25%
-35.02K
-2.31%
Mar 31, 2025
BVF Partners L.P.
1.45M
2.21%
-115.00K
-7.33%
Mar 31, 2025
Prosight Capital
1.31M
2%
+289.90K
+28.28%
Mar 31, 2025
Deep Track Capital LP
741.07K
1.12%
-39.71K
-5.09%
Mar 31, 2025
Finepoint Capital LP
656.59K
1%
-18.18K
-2.69%
Mar 31, 2025
Segall Bryant & Hamill, LLC
651.46K
0.99%
-34.41K
-5.02%
Mar 31, 2025
Hudson Bay Capital Management LP
565.00K
0.86%
+10.70K
+1.93%
Mar 31, 2025
Greenlight Capital, Inc.
482.75K
0.73%
+3.38K
+0.71%
Mar 31, 2025
Renaissance Technologies LLC
330.80K
0.5%
+34.70K
+11.72%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
1.24%
Avantis International Small Cap Equity ETF
0.12%
iShares Biotechnology ETF
0.09%
ActivePassive International Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Avantis Responsible International Equity ETF
0.02%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
Proportion1.24%
Avantis International Small Cap Equity ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.09%
ActivePassive International Equity ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Avantis Responsible International Equity ETF
Proportion0.02%
Avantis International Equity ETF
Proportion0.01%
iShares Health Innovation Active ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
